Discovery and Optimization of Novel Tricyclic Ubiquitin-Specific Protease 1 Inhibitors for the Treatment of BRCA-Mutated Breast Cancer
Year: 2025
Type: article
Language: en
Topic: Ubiquitin and proteasome pathways
Authors and affiliations:
raw_author_name: Tianning Xiong
raw_affiliation_strings: Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica
CAMS Key Laboratory of Small Molecule Immuno-Oncology Drug Discovery
Chinese Academy of Medical Sciences
Chinese Academy of Medical Sciences and Peking Union Medical College
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica
raw_author_name: Hong Yang
raw_affiliation_strings: Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Druggability Research for Cerebrovascular Diseases, Institute of Materia Medica
Chinese Academy of Medical Science and Peking Union Medical College
Chinese Academy of Medical Sciences and Peking Union Medical College
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica
Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Druggability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
raw_author_name: Songwen Lin
raw_affiliation_strings: Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica
CAMS Key Laboratory of Small Molecule Immuno-Oncology Drug Discovery
Chinese Academy of Medical Sciences
Chinese Academy of Medical Sciences and Peking Union Medical College
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica
raw_author_name: Li Sheng
raw_affiliation_strings: Chinese Academy of Medical Sciences and Peking Union Medical College
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica
raw_author_name: Junpu Ge
raw_affiliation_strings: Chinese Academy of Medical Sciences and Peking Union Medical College
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica
raw_author_name: Jinhua Wang
raw_affiliation_strings: Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Druggability Research for Cerebrovascular Diseases, Institute of Materia Medica
Chinese Academy of Medical Science and Peking Union Medical College
Chinese Academy of Medical Sciences and Peking Union Medical College
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Beijing Key Laboratory of Innovative Drug Discovery and Polymorphic Druggability Research for Cerebrovascular Diseases, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China
raw_author_name: Heng Xu
raw_affiliation_strings: Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica
CAMS Key Laboratory of Small Molecule Immuno-Oncology Drug Discovery
Chinese Academy of Medical Sciences
Chinese Academy of Medical Sciences and Peking Union Medical College
State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica